World-class hydrometallurgical experts to drive licensing, JV evaluation and scaling of proprietary RCL technology Highlights Scientific Advisory Board established to accelerate commercialization and global deployment of Temas' proprietary RCL technology. Board comprised of leading hydrometallurgical experts, strengthening technical credibility and execution capability. ...

Core Viewpoint - Ping An Biomedical Co., Ltd. has entered into a series of share purchase agreements with notable investors, enhancing its long-term development in biopharmaceutical R&D, medical technology, and innovation [1][2]. Investment Details - The investors include Yao Jinbo, Chairman and CEO of 58 Group Inc.; Wang Donghui, Founder and Managing Partner of Amiba Capital Co., Ltd; and Li Daxue, Chairman and CEO of Magcloud Group Co., Ltd [2]. - This investment round is seen as a strong endorsement of Ping An Bio's technology commercialization capabilities and long-term growth potential [4]. Investor Profiles - Yao Jinbo is recognized for his successful investments in sectors with structural growth opportunities, marking his second major investment in the pharmaceutical sector within a year [3][4]. - Wang Donghui emphasizes R&D capabilities and long-term value vision, managing RMB 5 billion in funds as of 2025, and recognizes Ping An Bio's potential for scalable growth [5]. - Li Daxue brings expertise in technology R&D and industrial integration, indicating strong market recognition of Ping An Bio's future transition towards industrialization and scalability [6]. Industry Position - Ping An Bio's simultaneous recognition from both "technology capital" and "industrial capital" highlights its unique position in the biopharmaceutical sector [7]. - The consensus among top-tier investors is expected to propel the company towards a broader global stage [7]. Management Commentary - Liu Pijun, Chairman and CEO of Ping An Bio, welcomes the new strategic investors, emphasizing their influence in technology innovation and capital operations [8]. - The company aims to deepen its AI systems and accelerate innovation in healthcare and biopharmaceutical technologies, striving to become a technology-driven global leader [9].